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Preventive Surgery is Associated with Reduced Cancer Risk and Mortality
in Women with BRCA1 and BRCA2 Mutations
Abstract
Women who have inherited mutations in the BRCA1 or BRCA2 (BRCA1/2) genes have a substantially
elevated risk of developing breast and ovarian cancer. For more than 10 years, researchers have studied
whether preventive surgery (to remove breasts, ovaries, and/or fallopian tubes) can reduce the cancer and
mortality risk in BRCA1/2 mutation carriers. This Issue Brief summarizes the results of the latest, largest,
multinational study on the effects of preventive surgery in these women. The results are consistent with earlier
studies and provide strong evidence for the use of preventive surgery as an effective approach to managing this
genetic risk.
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Preventive surgery is associated with reduced 
cancer risk and mortality in women with 
BRCA1 and BRCA2 mutations
Editor’s Note:  Women who have inherited mutations in the BRCA1 or BRCA2 
(BRCA1/2) genes have a substantially elevated risk of developing breast and ovarian 
cancer. For more than 10 years, researchers have studied whether preventive 
surgery (to remove breasts, ovaries, and/or fallopian tubes) can reduce the cancer 
and mortality risk in BRCA1/2 mutation carriers. This Issue Brief summarizes the 
results of the latest, largest, multinational study on the effects of preventive surgery 
in these women. The results are consistent with earlier studies and provide strong 
evidence for the use of preventive surgery as an effective approach to managing this 
genetic risk.
BRCA1/2 mutations confer a significant risk of breast and ovarian cancer. 
Clinical management options for these high-risk women include preventive 
salpingo-oopherectomy, (removal of the ovaries and fallopian tubes), preventive 
mastectomy, regular cancer screening, and chemoprevention. Each woman faces a 
complex and difficult decision about these options.
•	 BRCA1 and BRCA2 mutation carriers have a lifetime risk for breast cancer 
of 56%-84%; the lifetime risk for ovarian cancer is 36%-63% for BRCA1 
mutation carriers and 10%-27% for BRCA2 mutation carriers. These risks are 
substantially higher than in women in the general population, and reach the 
level that preventive measures must be considered to reduce the substantial risks 
of morbidity and mortality faced by these women.
•	 Preventive removal of both breasts (bilateral mastectomy) has been shown to 
reduce breast cancer risk by about 90%. However, the choice of this treatment 
option is complicated by concerns about quality of life and body image. 
Screening with yearly mammography or breast magnetic resonance imaging 
(MRI) is another option, although this strategy is designed to detect breast 
cancer early, rather than to prevent it. Chemopreventive options are also 
available for primary prevention of breast cancer.
•	 No effective screening strategies exist for ovarian cancer. Because of this and the 
high mortality rate associated with ovarian cancer, women are now advised to 
have risk-reducing salpingo-oopherectomy (RRSO) after their childbearing is 
completed and prior to age 35-40. Studies have shown that RRSO, which is the 
surgical removal of both ovaries and the fallopian tubes, reduces the risk of both 
ovarian and breast cancer.
Women with a BRCA1 or 
BRCA2 mutation face difficult 
decisions about how to 
reduce their risk of breast  
or ovarian cancer
Continued on next page.
•	 RRSO has become the standard of care for women with BRCA1/2 mutations, 
although many women do not choose this option. Premenopausal women 
face the difficult decision of undergoing a treatment that will cause abrupt 
and premature menopause and its attendant consequences on bone and 
cardiovascular health.
Meta-analysis of studies 
between 1999 and 2007 
reveals that RRSO is strongly 
associated with reductions in 
the risk of breast, ovarian, and 
fallopian tube cancers 
To provide an overall estimate of the risk reduction from RRSO, Rebbeck and 
colleagues conducted a meta-analysis of 10 studies of RRSO published between 
1999 and 2007.
•	 The pooled results of 5,703 participants across four separate studies indicate 
that RRSO is associated with a 50% reduction in the risk of breast cancer in 
BRCA1 and BRCA2 mutation carriers.
•	 The pooled results of 2,840 women across three separate studies indicate that 
RRSO is associated with an 80% reduction in the risk for ovarian/fallopian tube 
cancer in BRCA1 and BRCA2 mutation carriers.
•	 The data are lacking to evaluate the effects of birth cohort or timing of surgery.
•	 Limited data are available about differences for BRCA1 vs. BRCA2 mutation 
carriers in the efficacy of RRSO or risk-reducing mastectomy. However, it is 
clear that risk reduction is substantial in women with either mutation.
Prospective study conducted 
at 22 centers in Europe and 
North America
To clarify some of these remaining issues about the outcomes of preventive surgery, 
Domchek and colleagues analyzed data from the Prevention and Observation 
of Surgical Endpoints (PROSE) study, an international consortium of research 
centers. PROSE participants were ascertained between 1974 and 2008.
•	 The study included 2,482 women with BRCA1 or BRCA2 mutations at 22 
clinical and research genetics centers in Europe and North America. Some 
of the women had a prior diagnosis of breast cancer (i.e., one reason for 
undergoing genetic testing), while others did not.
• Women were eligible for the study if they had no prior ovarian cancer diagnosis 
and no diagnosis of cancer in the first six months of follow-up.
• Women who declined preventive mastectomy or RRSO were offered increased 
surveillance according to established guidelines. In the US, this consisted of 
annual mammography and MRI for those with breast tissue, and transvaginal 
ultrasound and CA 125 blood testing for those with ovaries. CA 125 measures 
a blood protein often elevated in ovarian cancer. However, CA 125 is not 
sufficiently sensitive or specific to be recommended for routine screening for 
ovarian cancer.
• Patients were followed prospectively from the time of their preventive surgery, 
or time they were identified for this study. The median time of follow-up was 
3.7 years for those who underwent surgery, and 4.3 years for those who did not.
Preventive surgery highly 
effective in reducing cancer 
risk and mortality
Overall, 10% of study participants chose risk-reducing mastectomy and 38% 
opted for RRSO. After adjusting for patient age and the ascertainment site, the 
authors found that preventive surgery was associated with large decreases in the 
incidence of cancer and in deaths from cancer and deaths from any cause.
•	 None of the 247 women who underwent prophylactic mastectomy developed 
breast cancer in the three years of follow-up, compared with 7% of women who 
did not have the surgery.
• Just 1% of women undergoing RRSO developed ovarian cancer, compared to 
6% of women who did not have the surgery. Women having RRSO also had a 
reduced risk of developing breast cancer (11% vs. 19%). 
• Undergoing RRSO (compared to those who did not) was associated with lower 
mortality from any cause (3% vs. 10%), lower mortality from breast cancer (2% 
vs. 6%) and lower mortality from ovarian cancer (0.4% vs. 3%).
• RRSO was associated with reduced risks for both BRCA1 and BRCA2 carriers, 
and in those with and without a prior diagnosis of breast cancer. See table below 
for specific risk reductions.
Synopsis of  
management strategies
The following table summarizes the management strategies available to women 
with BRCA1/2 mutations.
Management 
Option Strategy Advantage Limitation
Ovarian cancer
Chemoprevention Oral contraceptive pills Likely 30%-60% 
reduction in ovarian 
cancer risk
Potential increase risk  
of breast cancer
Screening Transvaginal  
ultrasound, serum
CA 125
Allows for screening 
prior to RRSO
Unproven efficacy
Risk-reducing surgery Bilateral RRSO About an 80% decrease 
in risks of ovarian and 
fallopian tube cancers
Infertility and  
premature menopause
Breast Cancer
Chemoprevention Selective estrogen 
receptor modulators 
(tamoxifen, raloxifene)
May reduce risk of 
breast cancer
Very limited  
data in BRCA1/2  
mutation carriers
Screening Yearly MRI
Yearly mammogram
Self/clinical breast 
examination
About 80% sensitive for 
detection of malignancy
Issues of specificity 
(false positives)
Does not prevent 
cancer, goal is  
early detection
Risk-reducing surgery Bilateral RRSO
Mastectomy, with 
or without breast 
reconstruction
About a 50% decrease 
in breast cancer risk
About a 90% reduction 
in breast cancer risk 
Premature menopause, 
iatrogenic infertility
Body image and 
quality-of-life issues
Risk Reduction Among Those Undergoing RRSO
BRCA1 carriers BRCA2 carriers
Prior history of 
breast cancer
85% reduction in ovarian cancer risk
No reduction in breast cancer risk
0 cases of ovarian cancer detected
No reduction in breast cancer risk
No prior history 
of breast cancer
70% reduction in ovarian cancer risk
37% reduction in breast cancer risk
0 cases of ovarian cases detected
64 % reduction in breast cancer risk
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The clinical management of cancer risk in BRCA1 and BRCA2 mutation carriers is 
complex and should consider patient preferences. These preferences can be informed 
by accurate knowledge of the risks and benefits of the interventions considered. 
• It is now clear that effective strategies exist for managing the elevated risks once the 
BRCA1/2 carrier status is known. Cancer risk estimates, and approaches to reducing 
those risks, should be incorporated into counseling for women who are BRCA1/2 
mutation carriers. Data on risks and benefits should be presented to help each 
woman make the best decision for herself. 
• These results can also help women make the initial decision about genetic testing 
for breast cancer. 
• A number of clinically relevant issues remain and warrant further research. The 
effect of age at RRSO remains unresolved. Some preliminary evidence suggests that 
the effects of RRSO on breast cancer risk reduction are greater before age 50 than 
after age 50. Another issue is the use of hormone replacement therapy after RRSO 
and its effect on the association of RRSO and reduced cancer risk. 
• Insurance coverage for risk-reducing surgery in BRCA1/2 mutation carriers is 
warranted. Many insurers now provide such coverage, although Medicare has no 
national coverage decision to that effect. Because the data on effectiveness are 
unequivocal, all public and private insurers should cover preventive surgery in  
these women.
